The results presented here show that CDK9 inhibitors suppress the growth of NSCLC cell lines and tumor organoids with high potency, with IC50s in the nanomolar range; CDK9 inhibitors were also effective against cell lines that were rendered resistant to the third-generation EGFR inhibitor Osimertinib [50,51,52], as well as the K-RasG12C inhibitor, AMG510 (Sotorasib) [53,54]. Here, CDK9 is linked to neoplasm.